Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

82.83 +0.20 (+0.24%)
Streaming Delayed Price Updated: 2:50 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Alcon Launches TOTAL30 Multifocal for Astigmatism, the World’s Only Monthly Multifocal Toric Contact Lens with Water Gradient Technology
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Completes $750 Million Share Repurchase Program
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Terminates Agreement to Acquire STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces Amended Merger Agreement with STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
From STAAR Surgical Company
Via Business Wire
News headline image
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
From Alcon Inc. Investors and STAAR Surgical Company
Via Business Wire
News headline image
STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
From STAAR Surgical Company
Via Business Wire
News headline image
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon to Present at 2025 Baird Global Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSE - WOW), BankFinancial Corporation (Nasdaq - BFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - CORZ)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Alcon Agrees to Acquire STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
News headline image
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces Results of 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Publishes Agenda for 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Agrees to Acquire LENSAR, Inc.
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon to Host 2025 Capital Markets Day
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters
From Alcon Canada
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.